🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Wonderful team effort from many people around the world. I want to take a second to especially thank our patients and families without whom we could not have accomplished this. We are in your debt. Shout out to the RET Renegades! nejm.org/doi/full/10.10…

From Phase 1 study to FDA approval in < 3 years & NEJM paper. Such a delight to work with a global team of amazing investigators, from 65 centers, in 12 countries ➡️Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell #lungcancer NEJM nejm.org/doi/full/10.10…

#rolemodel. The world needs more leaders like Dr. Aghajanian

Is this what trump meant when he said NYC is a ghost town?

With T-7, I need it send a happy one. There is nothing like one of your favorite fellows ⁦Robin Guo dressing up with you in clinic to make a few patients and their family members smile ... Halloween 2019.... only thing better is to have him to come on faculty at MSK !!

As we further subdivide NSCLC to personalize therapy, proteomics may complement genomics. Elegant and important work by Alexander Drilon MD Robin Guo Michael Offin Deepu Alex Ronglai Shen Ryma Benayed Charlie Rudin Natasha Rekhtman MD PhD Ahmet Zehir and the MSKCC team. #LCSM

MET IHC is back from the dead! We wrote it off as a biomarker, but pl see latest study from our group lead by Alexander Drilon MD & Robin Guo which found MET expression to predict TKI response in MET Ex 14-altered NSCLC. Twists & turns of the ever-evolving NSCLC biomarker story!

I am thankful to work with the best around. 💙 the #MSKNurses so much

Ending this mess of a year feeling hopeful. Took care of wonderful patients and this. Grateful for the science and the people who got it done. Bring it on 2021. #maskup #FauciOuchie #mskcc

Had a late night visit to @sloan_kettering’s Zuckerman building (more on that later) & saw a familiar #healthcarehero staring back at me: Alexander Drilon MD our Early Drug Development Chief - making major inroads in targeted therapies based on the science

My mentor, my sponsor, the best drug developer in the world and my friend from 16 years died today. I am where I am because of him and I am who I am because of him. I have no words.

Numb from news this morning of José Baselga's passing. Larger than life and a true giant of the field, he helped transform oncology care and saved countless lives. Personally, José also played a central role in my career. I will miss him dearly.

Jose left this world too soon. R.I.P. my friend

11 years ago I thought none of the following were possible: 10 years ago I came out to family and friends 🌈. 8 years ago I met my wife at Boston pride thanks to I. Glenn Cohen. 2 years later he legally married us. Today we celebrated #NYCPride with our 3 kids. #Pride2021

In a historic first, Dr. Valerie Rusch will be the first woman to be honored by the AATS Foundation Honoring Our Mentors program with the establishment of a mentored career development award in her name. Show your support for this valuable program: bit.ly/3hHFljp

We're so proud that MSK has the largest institutional representation in the Fellows of the AACR Academy class of 2022! Please RT and congratulate Drs. Luis Diaz, Thomas Kelly, Neal Rosen, Nikola Pavletich, and Alexander Rudensky. 🎉 bit.ly/3JvtccB

@DrEzraRosen Alexander Drilon MD Allison Betof Warner, MD, PhD Guilherme Harada Yonina Murciano-Goroff Dazhi Liu, Pharm.D, BCOP Robin Guo Memorial Sloan Kettering Cancer Center Omg is that Dr Mrinal Gounder too!

I’m heartbroken and angry to see another family, another community hurting due to police brutality. I stand with my hometown and the people of Memphis as we demand justice and accountability. #JusticeforTyreNichols

Breaking tradition can improve patient outcomes. In novel-known combinations where the novel drug is unlikely to work well alone, prolonged exposure to monotherapy in dose escalation is not patient-centric. This alternative FDA-approved phase I design poses a potential solution.

Pleased to present these new data at ASCO #ASCO23 and simultaneous publication in JCO. ascopubs.org/doi/abs/10.120… Here, we tested combination of encorafenib + binimetinib in patients metastatic BRAF V600E mutant NSCLC 1/